Literature DB >> 22483639

Renal cell neoplasms contain shared tumor type-specific copy number variations.

John M Krill-Burger1, Maureen A Lyons, Lori A Kelly, Christin M Sciulli, Patricia Petrosko, Uma R Chandran, Michael D Kubal, Sheldon I Bastacky, Anil V Parwani, Rajiv Dhir, William A LaFramboise.   

Abstract

Copy number variant (CNV) analysis was performed on renal cell carcinoma (RCC) specimens (chromophobe, clear cell, oncocytoma, papillary type 1, and papillary type 2) using high-resolution arrays (1.85 million probes). The RCC samples exhibited diverse genomic changes within and across tumor types, ranging from 106 to 2238 CNV segments in a clear-cell specimen and in a papillary type 2 specimen, respectively. Despite this heterogeneity, distinct CNV segments were common within each tumor classification: chromophobe (seven segments), clear cell (three segments), oncocytoma (nine segments), and papillary type 2 (two segments). Shared segments ranged from a 6.1-kb deletion (oncocytomas) to a 208.3-kb deletion (chromophobes). Among common tumor type-specific variations, chromophobes, clear-cell tumors, and oncocytomas were composed exclusively of noncoding DNA. No CNV regions were common to papillary type 1 specimens, although there were 12 amplifications and 12 deletions in five of six samples. Three microRNAs and 12 mRNA genes had a ≥98% coding region contained within CNV regions, including multiple gene families (chromophobe: amylases 1A, 1B, and 1C; oncocytoma: general transcription factors 2H2, 2B, 2C, and 2D). Gene deletions involved in histone modification and chromatin remodeling affected individual subtypes (clear cell: SFMBT and SETD2; papillary type 2: BAZ1A) and the collective RCC group (KDM4C). The genomic amplifications/deletions identified herein represent potential diagnostic and/or prognostic biomarkers.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22483639      PMCID: PMC3378847          DOI: 10.1016/j.ajpath.2012.01.044

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development.

Authors:  A van den Berg; T Dijkhuizen; T G Draaijers; M M Hulsbeek; E R Maher; E van den Berg; S Störkel; C H Buys
Journal:  Genes Chromosomes Cancer       Date:  1997-08       Impact factor: 5.006

Review 2.  Renal-cell carcinoma.

Authors:  Herbert T Cohen; Francis J McGovern
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

Review 3.  Tumor biology and prognostic factors in renal cell carcinoma.

Authors:  David S Finley; Allan J Pantuck; Arie S Belldegrun
Journal:  Oncologist       Date:  2011

4.  Segmental copy number loss of SFMBT1 gene in elderly individuals with ventriculomegaly: a community-based study.

Authors:  Takeo Kato; Hidenori Sato; Mitsuru Emi; Tomomi Seino; Shigeki Arawaka; Chifumi Iseki; Yoshimi Takahashi; Manabu Wada; Toru Kawanami
Journal:  Intern Med       Date:  2011-02-15       Impact factor: 1.271

Review 5.  The Heidelberg classification of renal cell tumours.

Authors:  G Kovacs; M Akhtar; B J Beckwith; P Bugert; C S Cooper; B Delahunt; J N Eble; S Fleming; B Ljungberg; L J Medeiros; H Moch; V E Reuter; E Ritz; G Roos; D Schmidt; J R Srigley; S Störkel; E van den Berg; B Zbar
Journal:  J Pathol       Date:  1997-10       Impact factor: 7.996

6.  Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.

Authors:  Michael L Nickerson; Erich Jaeger; Yangu Shi; Jeffrey A Durocher; Sunil Mahurkar; David Zaridze; Vsevolod Matveev; Vladimir Janout; Hellena Kollarova; Vladimir Bencko; Marie Navratilova; Neonilia Szeszenia-Dabrowska; Dana Mates; Anush Mukeria; Ivana Holcatova; Laura S Schmidt; Jorge R Toro; Sara Karami; Rayjean Hung; Gary F Gerard; W Marston Linehan; Maria Merino; Berton Zbar; Paolo Boffetta; Paul Brennan; Nathaniel Rothman; Wong-Ho Chow; Frederic M Waldman; Lee E Moore
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

Review 7.  Inherited forms of renal cell carcinoma.

Authors:  M Kiuru; M Kujala; K Aittomäki
Journal:  Scand J Surg       Date:  2004       Impact factor: 2.360

8.  Germline SDHB mutations and familial renal cell carcinoma.

Authors:  Christopher Ricketts; Emma R Woodward; Pip Killick; Mark R Morris; Dewi Astuti; Farida Latif; Eamonn R Maher
Journal:  J Natl Cancer Inst       Date:  2008-08-26       Impact factor: 13.506

9.  Inactivation of BHD in sporadic renal tumors.

Authors:  Sok Kean Khoo; Katherine Kahnoski; Jun Sugimura; David Petillo; Jindong Chen; Ken Shockley; John Ludlow; Robert Knapp; Sophie Giraud; Stéphane Richard; Magnus Nordenskjöld; Bin Tean Teh
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

10.  Virtual karyotyping with SNP microarrays reduces uncertainty in the diagnosis of renal epithelial tumors.

Authors:  Jill M Hagenkord; Anil V Parwani; Maureen A Lyons-Weiler; Karla Alvarez; Robert Amato; Zoran Gatalica; Jose M Gonzalez-Berjon; Leif Peterson; Rajiv Dhir; Federico A Monzon
Journal:  Diagn Pathol       Date:  2008-11-06       Impact factor: 2.644

View more
  10 in total

1.  Large (>3.8 cm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous.

Authors:  Laura Zaldumbide; Asier Erramuzpe; Rosa Guarch; Jesús M Cortés; José I López
Journal:  Virchows Arch       Date:  2014-11-05       Impact factor: 4.064

2.  A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies.

Authors:  Dennis Gürgen; Michael Becker; Mathias Dahlmann; Susanne Flechsig; Elke Schaeffeler; Florian A Büttner; Christian Schmees; Regina Bohnert; Jens Bedke; Matthias Schwab; Johann J Wendler; Martin Schostak; Burkhard Jandrig; Wolfgang Walther; Jens Hoffmann
Journal:  Front Oncol       Date:  2022-06-21       Impact factor: 5.738

3.  Amylase α-1A (AMY1A): a novel immunohistochemical marker to differentiate chromophobe renal cell carcinoma from benign oncocytoma.

Authors:  Sarika Jain; Somak Roy; Milon Amin; Marie Acquafondata; Ming Yin; William Laframboise; Sheldon Bastacky; Liron Pantanowitz; Rajiv Dhir; Anil Parwani
Journal:  Am J Surg Pathol       Date:  2013-12       Impact factor: 6.394

4.  SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.

Authors:  Lianjie Li; Chuan Shen; Eijiro Nakamura; Kiyohiro Ando; Sabina Signoretti; Rameen Beroukhim; Glenn S Cowley; Patrick Lizotte; Ella Liberzon; Steven Bair; David E Root; Pablo Tamayo; Aviad Tsherniak; Su-Chun Cheng; Barbara Tabak; Anders Jacobsen; A Ari Hakimi; Nikolaus Schultz; Giovanni Ciriello; Chris Sander; James J Hsieh; William G Kaelin
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

5.  Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes.

Authors:  Siân Jones; Nicolas Stransky; Christine L McCord; Ethan Cerami; James Lagowski; Devon Kelly; Samuel V Angiuoli; Mark Sausen; Lisa Kann; Manish Shukla; Rosemary Makar; Laura D Wood; Luis A Diaz; Christoph Lengauer; Victor E Velculescu
Journal:  Nat Commun       Date:  2014-09-19       Impact factor: 14.919

6.  Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors.

Authors:  Jiqiu Cheng; Jonas Demeulemeester; David C Wedge; Hans Kristian M Vollan; Jason J Pitt; Hege G Russnes; Bina P Pandey; Gro Nilsen; Silje Nord; Graham R Bignell; Kevin P White; Anne-Lise Børresen-Dale; Peter J Campbell; Vessela N Kristensen; Michael R Stratton; Ole Christian Lingjærde; Yves Moreau; Peter Van Loo
Journal:  Nat Commun       Date:  2017-10-31       Impact factor: 14.919

7.  Stratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysis.

Authors:  H-J Thiesen; F Steinbeck; M Maruschke; D Koczan; B Ziems; O W Hakenberg
Journal:  PLoS One       Date:  2017-05-09       Impact factor: 3.240

8.  iPSC-Derived Embryoid Bodies as Models of c-Met-Mutated Hereditary Papillary Renal Cell Carcinoma.

Authors:  Jin Wook Hwang; Christophe Desterke; Olivier Féraud; Stephane Richard; Sophie Ferlicot; Virginie Verkarre; Jean Jacques Patard; Julien Loisel-Duwattez; Adlen Foudi; Frank Griscelli; Annelise Bennaceur-Griscelli; Ali G Turhan
Journal:  Int J Mol Sci       Date:  2019-09-30       Impact factor: 5.923

9.  Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study.

Authors:  Renaud Sabatier; Cécile Vicier; Séverine Garnier; Arnaud Guille; Nadine Carbuccia; Nicolas Isambert; Florence Dalenc; Marie Robert; Christelle Levy; Jihane Pakradouni; José Adelaïde; Max Chaffanet; Patrick Sfumato; Emilie Mamessier; François Bertucci; Anthony Goncalves
Journal:  Mol Oncol       Date:  2022-03-30       Impact factor: 7.449

10.  Subtyping of renal cortical neoplasms in fine needle aspiration biopsies using a decision tree based on genomic alterations detected by fluorescence in situ hybridization.

Authors:  Banumathy Gowrishankar; Lynnette Cahill; Alexandra E Arndt; Hikmat Al-Ahmadie; Oscar Lin; Kalyani Chadalavada; Seeta Chaganti; Gouri J Nanjangud; Vundavalli V Murty; Raju S K Chaganti; Victor E Reuter; Jane Houldsworth
Journal:  BJU Int       Date:  2014-07-15       Impact factor: 5.588

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.